The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Hyperlipidemia: Focus on Therapeutic Implications

Author： Farnier Michel  

Publisher： Adis International

ISSN： 1175-3277

Source： American Journal of Cardiovascular Drugs, Vol.11, Iss.3, 2011-06, pp. : 145-152

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia

By  

Current Pharmaceutical Design, Vol. 23, Iss. 10, 2017-05 ,pp. : 1495-1499

Bentham Science Publishers

Access to resources Recommend Favorite

Proprotein Convertase Subtilisin/kexin type 9 Inhibition in Cardiovascular Prevention

By  

Current Pharmaceutical Design, Vol. 24, Iss. 4, 2018-04 ,pp. : 442-450

Bentham Science Publishers

Access to resources Recommend Favorite

Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia

By Lee Paul   Hegele Robert A  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 11, 2013-11 ,pp. : 1411-1423

Informa Healthcare

Access to resources Recommend Favorite

Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents

By Abifadel Marianne   Pakradouni Jihane   Collin Matthieu   Samson-Bouma Marie-Elisabeth   Varret Mathilde   Rabès Jean-Pierre   Boileau Catherine  

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 11, 2010-11 ,pp. : 1547-1571

Informa Healthcare

Access to resources Recommend Favorite

The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins

By  

Current Pharmaceutical Design, Vol. 23, Iss. 10, 2017-05 ,pp. : 1477-1483

Bentham Science Publishers

Access to resources Recommend Favorite